Podcast appearances and mentions of Johnson Johnson

Episode 10 - Stephanie Karzon Abrams: Heart and Science This episode takes on a wide ranging ride inside Stephanie's wildy diverse experise on the science of psychedelics to the importance of music and community. Stephanie is a profound and powerful voice in the psychedelic community and her work represents the best of the modern psychedelic movement.  Intro: Ann Shulgin takes on a brief exploration of the shadow.  Stephanie Karzon Abrams is a neuropharmacologist, founder of Beyond Consulting—powering the integrative, psychedelic and plant medicine spaces, and is the co-founder of the Public Secret music label and artist collective.  She serves as Clinical Director at Modern Medicine Services, is a prescriber of MDMA and psilocybin therapy under Canada's SAP, and is the Research Director at the Microdosing Collective non profit.  Stephanie believes in the undercurrent of joy woven into the fabric of our existence and thus co-created the talk and event series "The Chemistry of Joy", where the human experience is explored through the lens of ritual and celebration.  With experience in neurology, intensive care, and medical device at Johnson & Johnson, she is a recognized leader in innovative healthcare. Her work bridges neuroscience, women's health, plant medicine, and the healing power of music. A musician, writer, and speaker, Stephanie also builds community through gatherings rooted in music, meaning, and mycology. Web: https://www.stephaniekarzonabrams.com  Www.Beyondconsulting.Life  Social: @steph__k @public.secret  @microdosingcollective @thechemistryofjoy @mod_meds

In this short podcast episode, Bryan explains how duct tape got its name and why it shouldn't actually be used on ducts. Duct tape is a versatile home DIY-fix tool, but despite its name, it wasn't initially made to seal ducts at all. In 1943, we were in the thick of World War II, and ammo shipments were sealed with wax and paper tape. These were often not durable or difficult to open. Johnson & Johnson developed a tape with rubber adhesive on a cotton duck cloth backing (which was already widely used for military uniforms and tent fabrics). This new tape was nicknamed "duck" tape due to the material and its waterproof abilities (like the waterfowl). A woman named Vesta Stoudt informed President FDR about duct tape, and the War Production Board began using it in wartime supply packaging. After the war, America had a housing boom in the 1950s, which included the demand for forced-air heating and cooling systems. Marketers thought the tape could seal the ducts in those homes, so they changed the color to match sheet metal and rebranded it as "duct tape." In the 1960s, this tape was available in retail outlets with the "duct tape" branding. Unfortunately, in tests by the Lawrence Berkeley National Lab, duct tape failed miserably at sealing the ducts because the rubber adhesive dries out under heat, and dust weakens the adhesive. As a result, many building codes ban duct tape on ducts (spearheaded by California). Instead, UL-listed foil tape and mastic are approved for sealing ducts. However, duct tape still became famous for its versatility as a patching material. It's prevalent in pop culture and has been used in television shows and even in space.   Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android.

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson, alleging the company failed to warn that Tylenol taken during pregnancy could increase the risk of autism and ADHD. The move comes after President Trump's remarks on ignited public debate on the cause of autism and the safety of Tylenol.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This Day in Legal History: Black TuesdayOn October 29, 1929, the United States experienced one of the most catastrophic financial events in its history—Black Tuesday, the climax of the stock market crash that helped trigger the Great Depression. While primarily remembered as an economic crisis, this day also had profound and lasting legal consequences that reshaped American financial regulation and the federal government's role in the economy.In the immediate aftermath, the lack of oversight and rampant speculation that had fueled the 1920s bull market came under intense scrutiny. The legal system responded in the 1930s with a suite of landmark legislative reforms designed to stabilize financial markets and restore public confidence. Chief among these were the Securities Act of 1933 and the Securities Exchange Act of 1934, which established mandatory disclosure requirements for public companies and created the Securities and Exchange Commission (SEC) to enforce federal securities laws.These laws introduced the legal principle that corporations owe a duty of candor to investors and that misleading or fraudulent statements can be subject to civil and criminal penalties. They also laid the foundation for modern financial regulation, including rules governing insider trading, market manipulation, and fiduciary duties of brokers and advisors.The legal legacy of October 29, 1929, is thus not limited to market losses but includes the birth of a federal regulatory framework that continues to govern securities markets today. It marked a turning point where the federal government took a permanent role in policing Wall Street and protecting investors through statutory and administrative mechanisms.The U.S. Court of Appeals for the Second Circuit will hear Argentina's appeal of a $16.1 billion judgment related to its 2012 expropriation of oil company YPF. The judgment, issued by U.S. District Judge Loretta Preska in 2023, awarded $14.39 billion to Petersen Energia Inversora and $1.71 billion to Eton Park Capital Management, former minority shareholders of YPF. They claimed Argentina violated contractual obligations by failing to make a tender offer when it nationalized 51% of YPF from Spanish energy firm Repsol.Argentina argues the case should not be heard in a U.S. court, citing sovereign immunity, misapplication of Argentine law, and the principle of international comity. It also contends the damages are vastly overstated—amounting to 45% of its 2024 national budget. The litigation has been financially backed by Burford Capital, which could receive a large payout if the appeal fails.The appeal arrives as President Javier Milei, a libertarian reformer, works to stabilize Argentina's economy with austerity measures, having recently achieved a rare budget surplus. Meanwhile, Argentina is also separately appealing a court order to hand over YPF shares, an order currently on hold. The U.S. government has not taken a stance on the appeal but opposed the share turnover, citing foreign policy risks.Argentina to ask US appeals court to overturn $16.1 billion YPF judgment | ReutersA federal judge ruled that Bilal Essayli was unlawfully appointed as acting U.S. attorney for California's Central District, which includes Los Angeles. U.S. District Judge J. Michael Seabright found that Essayli's continued service beyond the 120-day interim period allowed by law was improper since he had neither been nominated by the president nor confirmed by the Senate. This decision disqualifies him from serving in the acting role but allows him to remain as first assistant U.S. attorney.The ruling does not dismiss three criminal indictments issued during Essayli's tenure, as they were signed by other prosecutors and no due process violations were found. Still, the judgment raises concerns about leadership stability in the largest federal judicial district in the country, serving roughly 19 million people.Essayli's appointment was part of a broader pattern under the Trump administration of bypassing Senate confirmation for key prosecutorial roles. A similar ruling recently invalidated the acting U.S. attorney appointment in Nevada, and another decision in New Jersey blocked Alina Habba, a Trump ally, from participating in prosecutions. These appointments are now under appeal.Judge disqualifies ‘acting' US attorney in California | ReutersThe celebrity video platform Cameo filed a trademark infringement lawsuit against OpenAI in a California federal court, accusing it of unlawfully using the name “Cameo” for a new feature in its Sora video generation app. Cameo claims that OpenAI's use of the term for AI-generated virtual likenesses causes brand confusion and threatens the distinctiveness of its trademark.OpenAI launched Sora as a standalone app in late September, and its feature—also named “Cameo”—lets users create AI-generated videos that can include virtual celebrities. Cameo argues this directly competes with its own service, where users pay real celebrities for personalized video messages. The company pointed to examples of AI-generated videos featuring public figures like Mark Cuban and Jake Paul, claiming this puts OpenAI in head-to-head competition with their business model.Cameo said it attempted to resolve the issue privately, but OpenAI declined to change the feature's name. OpenAI responded that it disagrees with the lawsuit, arguing no one can monopolize a generic term like “cameo.”The lawsuit seeks financial damages and a court injunction to stop OpenAI from using the name “Cameo.”OpenAI sued for trademark infringement over Sora's ‘Cameo' feature | ReutersTexas has hired the law firm Keller Postman—which previously secured a $1.4 billion settlement from Meta—to lead a new lawsuit alleging that Tylenol use during pregnancy increases the risk of autism in children. Filed in Panola County, the suit accuses Johnson & Johnson and Kenvue, Tylenol's current owner, of misleading consumers by marketing the drug to pregnant women despite knowing potential developmental risks tied to its active ingredient, acetaminophen.Ashley Keller, a senior partner at the firm, said the case will be handled on a contingency basis, meaning Texas pays only if it wins, similar to prior deals with Meta and Google. The firm's effective hourly rate under that model can reach $3,780, though its total fees are capped at 11% of any recovery. Keller defended the state's approach, saying the firm invests heavily and shares the litigation risk with Texas.The lawsuit builds on ongoing national litigation over acetaminophen and childhood developmental disorders, though courts have previously rejected similar claims. A 2024 federal ruling in New York dismissed related cases after expert testimony linking acetaminophen to ADHD was excluded. Texas' case, however, is distinct because it focuses on state-level claims of deceptive trade practices and fraudulent transfer, alleging J&J unlawfully moved Tylenol liabilities to Kenvue.Texas Returns to Keller Postman to Link Tylenol to Child Autism This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

This week on the Power of Owning Your Career Podcast, host Simone Morris welcomes Keith Willis—leadership expert, entrepreneur, and Founder of Core Management Training. Keith's journey is indicative of how careers thrive by intentional design, not by chance. Starting out as a U.S. Army Junior Officer, Keith made the leap to corporate America through the Cameron-Brooks Development & Preparation Program, a pivotal experience that shaped his passion for helping others own their career trajectories. Keith built an impressive resume with award-winning roles in sales and training at industry giants such as Johnson & Johnson, Pfizer, and Bristol Myers Squibb, where he was recognized for his results as both a sales representative and a manager. Inspired by his drive to close the gap between individual performance and transformative leadership, Keith founded Core Management Training, where he equips pharmaceutical and life sciences organizations to turn managers into leaders who drive performance and culture. Today, Keith is also building "Never Look for a Job Again"—an e-zine and course designed to empower professionals to create opportunities rather than wait for them. He believes that anyone can own their career by embracing self-awareness, setting meaningful goals, and building supportive networks. In this candid and practical conversation, Keith shares actionable advice on navigating uncertainty, addressing ageism, and staying true to your authentic self—even when the workplace challenges you to fit in. Listeners will take away Keith's holistic formula for career ownership, practical resources, and the confidence to make bold moves—no matter where they're starting from. Resources Mentioned in the Episode: Never Look for a Job Again (career development guide and upcoming course) PCS to Corporate America by Cameron Brooks Manager Tools & Career Tools podcasts The Long View by Brian Fetherstonhaugh Self-development tools: Audible, LinkedIn Learning, and yes—even ChatGPT! Connect & Learn More: Host Simone E. Morris: LinkedIn | Become a Guest on the Show | 52 Tips for Owning Your Career Keith Willis: Core Management Training | Never Look for a Job Again Follow & Subscribe: Join us on IG at @simonemorrisent for career inspiration Subscribe to our YouTube for inclusive conversations and actionable career strategies Whether you're an aspiring leader, a career changer, or someone looking to unlock your full potential, this episode will inspire you to get behind the wheel of your career and drive your future forward.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Khoảng 3.000 người tại Anh khởi kiện Johnson & Johnson, cáo buộc hãng biết rõ phấn rôm chứa amiăng gây ung thư nhưng vẫn bán ra thị trường. Vụ kiện đòi bồi thường hơn 1 tỉ bảng, làm dấy lên tranh cãi về độ an toàn của sản phẩm.

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, de la reanudacion de la guerra comercial entre China y EEUU, del discurso de Jerome Powell y de una posible crisis en el credito privado. Nos da los reportes de ingresos de los bancos, de Domino's Pizza, de Johnson & Johnson, ASML y JB Hunt. Después habla de unas inversiones estrategicas y de una fusion de las madereras. Finalmente da un pequeño crypto update donde habla de la confiscada mas grande en la historia y el error de dedo mas espectacular antes de contestar a unas preguntas de los Emprendeduros. ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

United Kingdom correspondent Lucy Thomson spoke to Lisa Owen about the boss of MI5 intervening in a row over the collapse of the alleged Chinese spy case, as well as Johnson & Johnson facing legal action from thousands of people in the UK.

Johnson & Johnson reported its latest earnings and announced a separation of its orthopedics business into a standalone company. CEO Joaquin Duato discusses the company's next era, new warning labels for its multiple myeloma treatment Carvykti, and the future of J&J's consumer. Then, it's publication day for Andrew Ross Sorkin's new book 1929, which details the stock market crash that reshaped American capitalism. Plus, China sanctions a South Korean shipbuilder accused of aiding the U.S., and President Trump weighs in on a two-state solution and rebuilding Gaza. Joaquin Duato - 10:25 In this episode:Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber discussed stock markets down sharply after Monday's rebound rally — as trade tensions between the U.S. and China re-escalate. The anchors also delved into big banks kicking off earnings season, including quarterly results from JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup. BlackRock Chairman & CEO Larry Fink joined the show at Post 9 to talk about earnings as well as the investment landscape both globally and in the U.S. Also in focus: The latest on OpenAI, hear what Oracle's new CEOs and Broadcom CEO Hock Tan had to say about AI, Johnson & Johnson's upbeat quarterly results and outlook. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

(The Center Square) — Before President Trump warned pregnant women to avoid taking Tylenol, three members of Congress dumped stock in the Fortune 500 company that makes the popular painkiller -- sell-offs that saved them from incurring sizable losses, an investigation by The Center Square found. The lawmakers sold $1,001 to $15,000 each in Kenvue Inc., a Summit, New Jersey-based consumer products company that spun off from Johnson & Johnson two years ago. The sales are notable also because most investment analysts recommended that investors hold their shares. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Lauren Livak Gilbert is the Executive Director of the Digital Shelf Institute (DSI), which shapes the future of digital and advances commerce through community, content, and education. In her role, she defines the strategy for creating a global industry commerce community to support brands, retailers, and future leaders in the complex digital environment. As a thought leader in digital and design, Lauren has over 10 years of experience driving impactful multichannel design content, transformative digital shelf solutions, and high-conversion web UX designs across multiple regions. Before DSI, she held numerous roles at Johnson & Johnson, where she owned the digital shelf for consumer products in North America. In this episode… The pace of change in digital commerce has forced brands to rethink their organizational structures. Traditional structures built solely for brick-and-mortar sales can no longer keep up with evolving customer expectations and constant platform updates. How can brands transform their organizations to stay relevant in the omnichannel marketplace? Seasoned digital commerce strategist Lauren Livak Gilbert urges brands to transform their overall operations instead of merely choosing where eCommerce belongs in the company. Presenting yourself to retailers as a single unified company, setting shared goals across teams, and using AI to automate tasks like forecasting and content creation are essential. Lauren also highlights the need for clean, standardized data and advises HR leaders to prepare the next generation of digital talent. These shifts position businesses to adapt quickly and thrive. In this episode of The Digital Deep Dive, Aaron Conant sits down with Lauren Livak Gilbert, Executive Director of The Digital Shelf Institute (DSI), to discuss building the reinvented omnichannel organization of the future. Lauren explains why shared goals drive higher eCommerce sales, how AI frees teams for strategic thinking, and why HR must rethink talent development.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Whether you've ever been a boss or have ever had a boss, you know how much those singular individuals can shape the workplace. According to studies, a good manager can increase employee engagement by as much as 70%. And, according to a survey by the American Psychological Association, a whopping 75% of employees report their boss as the worst and most stressful part of their jobs.  So, how do we know if we're being a good boss or a bad boss?  Do we just know, or should we be looking out for specific things?   Enter the incredible stories that focus on what good leaders can learn from bad bosses, featuring the author of the brand-new book, The Devil Emails at Midnight, Mita Mallick.   What to listen for: The importance of time in creating a healthier workplace culture Accountability - and how to hold others accountable, as well as check in with yourself What boss archetypes Mita has found most personally challenging  The keys to being a good boss  About our guest   Mita Mallick is a Wall Street Journal and USA Today best-selling author. She's on a mission to fix what's broken in our workplaces. She's a corporate change-maker with a track record of transforming businesses and has had an extensive career as a marketing and human resources executive. Mallick has brought her talent and expertise to companies like Unilever, Pfizer, AVON, Johnson & Johnson, Carta, and more. She's a highly sought-after speaker and business coach to start-up founders, executives, and CEOs of public companies. Her highly anticipated second book, "The Devil Emails at Midnight: What Good Leaders Can Learn from Bad Bosses," comes out September 30, 2025.    For more about the book or to purchase The Devil Emails at Midnight:  What Good Leaders Can Learn From Bad Bosses, click here:  https://www.amazon.com/dp/1394316488

About the Guest(s): Dr. Kristin Hieshetter is the host of "Functional Health Radio" and an advocate for holistic health and well-being. With extensive experience in the field of functional health, Dr. Hieshetter addresses controversial subjects in health and wellness with a focus on empathetic and fact-based conversations. Her work often involves dissecting complex medical topics and bringing light to issues that impact public health. Episode Summary: In this riveting episode of "Functional Health Radio," Dr. Kristin Hieshetter dives deep into the controversy surrounding Tylenol (acetaminophen) and its implications for pregnant women and children's health. As part two of a compelling series, Dr. Hieshetter meticulously examines studies suggesting links between acetaminophen use during pregnancy and increased risks of autism, ADHD, and other neurodevelopmental disorders in children. This episode highlights the historical, medical, and ethical concerns tied to one of the most commonly used over-the-counter medications in the world. This discussion centers around research showing acetaminophen's potential as an endocrine disruptor capable of affecting fetal brain development, with notable studies like the 2019 Journal of the American Medical Association Psychiatry article and others from UCLA and Sweden exploring this connection. Dr. Hieshetter raises awareness of these significant findings, intertwining scholarly data with her professional insights, and encourages listeners to approach this complex issue with open-mindedness and a commitment to understanding the broader implications on public health. Key Takeaways: Acetaminophen (Tylenol) use during pregnancy has been linked to increased risks of autism, ADHD, and other neurodevelopmental disorders, according to various studies. Historical issues with Johnson & Johnson's products, such as asbestos in talcum powder, highlight concerns about trust and corporate responsibility. The notion that acetaminophen disrupts hormone function during pregnancy, potentially influencing fetal brain development, is supported by multiple research findings. There is a call for further investigations and dialogue about the safety of acetaminophen, particularly concerning its use in pregnant women and children. Alternative methods for managing fever and pain, especially during pregnancy, should be considered to minimize potential risks to fetal development. Notable Quotes: "We were propagandized to believe that certain medications are safe, and now we're facing the consequences of that trust." "If this is truly what's happening, as these researchers have said, it warrants additional investigation." "The rapid increase in childhood neurodevelopmental disorders in the United States of America is unacceptable." "Maternal acetaminophen use during pregnancy is linked to a 37% rise in hyperkinetic disorders and 29% in ADHD." "We must have honest conversations about the world we've created and the legacy we want to leave behind." Resources: Journal of the American Medical Association Psychiatry (2019) - Link UCLA Study (2014) on acetaminophen and neurodevelopmental disorders. Johnson and Johnson No More Tears expose by Gardner Harris. EWG Water Safety Reports - Link Alternative Medicine Review (2009) on acetaminophen and autism. Listeners are encouraged to absorb the insights and data shared in this episode and reflect on the broader implications of acetaminophen use. For more enlightening discussions, stay tuned to "Functional Health Radio" and explore different avenues for enhancing personal and public health.

In this week's episode, we revisit our interview with Karen Long, a Managing Director at KCK (Med Tech) Group. KCK focuses on capital investment in commercial and growth-stage medical device companies. Karen has been with KCK since January 2018, when she joined as Executive-in-Residence. Karen serves as Board Director in many KCK portfolio companies as well as Independently. Prior to KCK, Karen was President and CEO of Nuelle, a women's consumer health company incubated at ExploraMed, a Silicon Valley medical device incubator. Nuelle was acquired in 2017. Karen has spent over 20 years in medical devices and diagnostics developing and marketing novel and market leading products focused on improving quality of life. She has held a series of key operating roles in consumer diagnostic companies, ChemTrak and Inverness Medical and eventually management positions at LifeScan, a Johnson & Johnson company, after the acquisition of Inverness Medical. In early 2007, Karen joined Acclarent as Worldwide Vice President of Marketing and led Acclarent's marketing efforts through rapid growth and ultimately through the acquisition by Johnson & Johnson. Karen held remained at Johnson & Johnson until joining the ExploraMed incubator in 2012. Acclarent was also an early spinout from ExploraMed. Karen began her career as a Licensed Clinical Social Worker after receiving her undergraduate and graduate degrees from San Diego State University.

How can college students step out of their comfort zone? Tim Conniff is a Keynote Speaker. He offers keynote talks that combine stand-up comedy along with a motivational message on the importance of getting out of your comfort zone, overcoming failures and avoiding negative self-talk, with clients such as Aetna, Corning, Dow Jones, Johnson & Johnson, and many more. In episode 599 of the Fraternity Foodie Podcast, we find out why Tim chose the University of Scranton, what inspired him to transition into keynote speaking and comedy, when he realized he needed to step out of his own comfort zone, what are the four zones of comfort, fear, learning, and growth, how you can reframe failure as feedback, how you can silence the inner critic and replace negative self-talk with resilience-building habits, why humor is such an effective tool for teaching personal growth, what is Tim's favorite interactive moments from a keynote, and how his message helps students find courage. Enjoy!

Ever stared at a toothpaste tube and wondered if it could take you higher? In episode 18 of Rabbit Hole, Billy Merritt and the BIT Comedy players tumble from dental conspiracies and Norwegian stop-motion cartoons to hoarding hotel soaps, prank-calling Captain Crunch, and even a pirate gang in juvie. Along the way, fluoride turns into Flo Rida, the Soggies declare war, and toothpaste becomes the most questionable substance at the Cannabis Cup. It's improv chaos at its finest: absurd connections, quick character swaps, and the kind of storytelling detours only this ensemble could conjure. From corporate “green peas” to Plato's cave, with a bit of toothpaste smoke in the air, this Rabbit Hole has it all.

A two-day conference which will examine cutting-edge technology, best practice and leadership in Maintenance, Reliability and Asset Management will be held in Kilkenny later this month. The conference will bring together over 35 exhibitors and 250 leaders from the pharmaceutical, biotech, medical device, life science, manufacturing, aerospace, industrial engineering and energy sectors. 'Reliability Ireland' takes place at the Lyrath Hotel, Kilkenny on Tuesday, September 23rd and Wednesday, September 24th. The event is designed for professionals who ensure the reliability and performance of systems, machinery, and infrastructure, as well as those shaping organisational strategy. It brings together individuals aligning asset management initiatives with broader business goals including strategy and sustainability objectives. The event will feature 18 Irish and International keynote and industry speakers, including former Ireland and Lions Rugby Captain Brian O'Driscoll; Aeronautical Engineer and STEM Advocate, Dr Norah Patten; The Mental Fitness Coach, Neil O'Brien of SkillStack; Digital Transformation and AI Specialist Kevin Rad; RCM expert Nancy Regan; with industry leaders and experts from Eli Lilly, Boston Scientific, Johnson & Johnson, Digital Manufacturing Ireland, ASHRAE and many more. The Mental Fitness Coach, Neil O'Brien of Skillstack, will be highlighting the importance of getting the basics in business right. He said: "A lot of my clients are in elite sports and I always tell them that those who achieve the best results are those who are getting the basics right and this advice can be applied to any business. Whether it's customer service, sales or leadership, a company needs to ensure that these are being done better than the competition to get ahead." Another area to be explored is AI-driven strategies in business. Digital Transformation and AI Specialist Kevin Rad said: "Companies using AI-driven strategies are already seeing a reduction of 50% in unplanned maintenance downtime and their maintenance costs have decreased by a quarter. Businesses that embrace these tools are positioning themselves ahead of the curve in efficiency, reliability, and asset performance." Bernard Yore, CEO of ESS Group, which organises the event, describes Reliability Ireland as more than a conference and exhibition. He said, "It is a foundational platform for all things reliability, maintenance and asset management. It is essential for engineers and asset management professionals looking to lead through technology, best practices and leadership." Reliability Ireland is a biennial event designed by industry, for industry and was established in 2016. Registration closes on Thursday, September 18th. For more information or to register, visit https://reliabilityireland.ie/. The key themes of Reliability Ireland 2025 are: Strategy, Leadership and Workforce Development AI, Next-Gen Technology and Digital Transformation Benchmarking, Best Practice and Data-Driven Insights Sustainability, ESG and Future-Proofing Assets Condition Monitoring and Predictive Analytics More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

In this episode of Investor Connect, Hall Martin speaks with Rachna Dayal, a global health biotech and venture investment expert, founder of Sugati Ventures.  Rachna shares her transition from corporate roles at Johnson & Johnson and Philips to founding and running a venture fund focused on transformative health tech startups. She talks about the major differences between working in large corporations and managing a small VC fund, emphasizing the importance of flexibility and addressing high unmet needs in healthcare through innovative solutions in medical devices and AI-enabled platforms.  Rachna highlights her investment thesis around consumer-first, purpose-led brands, particularly focusing on life-saving devices and enhancing quality of life, and discusses the crucial role of founder-market fit and diverse backgrounds in fostering innovation in the healthcare space. She also touches on current trends such as the rise of AI in healthcare and the impact of economic conditions on venture capital, offering advice for new investors and emphasizing the need for perseverance during tough times in the investment landscape.  Visit Sugati Ventures at Reach out to at   _______________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

What if the real secret to exceptional leadership isn't control, charisma, or even performance—but generosity? Could the “soft stuff” like listening, empathy, and vulnerability truly drive the hardest results in business? In this episode of the Delighted Customers podcast, I dig into that very question with Joe Davis, legendary former Senior Partner at Boston Consulting Group, co-founder of BCG's Washington D.C. office, and author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain”. Joe shares his own journey from traditional, results-driven leadership to a generous, people-centered model—and why unlocking your team's full human potential just might be the most powerful business move you can make. We explore how the traits of generosity drive not only team happiness and loyalty, but also real bottom-line outcomes, making this conversation essential listening for leaders and aspiring leaders at every level. Why should you tune in to this episode? Joe has four decades of hands-on experience innovating in both the private and public sectors, founding major business initiatives within BCG, and working closely with Fortune 500 C-suite leaders. He distills this wisdom into practical strategies—whether you're leading a team of three or a global enterprise of 100,000. His stories from the front lines of consulting, combined with actionable steps for building trust and humanity in the workplace, will change the way you think about leadership forever. Here are three compelling questions Joe answers on the show: Why should organizations and their C-suite invest in “generous leadership” when they're held accountable for hard business outcomes, not just a healthy culture? What are the seven key traits that separate good leaders from exceptional, generous leaders—and how do they play out in real-world scenarios? How can listening, vulnerability, and small acts of recognition dramatically improve your team's performance and engagement? Listen now and subscribe to the Delighted Customers podcast on Apple Podcasts and Spotify! You'll find this episode—and every episode—on all your favorite podcast platforms. If you find value in these conversations, please leave a review and share with a friend or colleague who wants to rethink what great leadership really looks like. Meet Joe Davis Joe Davis is a veteran senior partner at Boston Consulting Group (BCG), where he spent 37 years shaping strategy, developing talent, and transforming organizations at the highest level. Joe co-founded BCG's Washington D.C. office and launched the firm's North American Public Sector business, as well as leading BCG North America. Passionate about advancing equity and inclusion, he also founded and chaired BCG's Center for Inclusion and Equity. Joe is a Harvard Business School graduate and has been at the forefront of helping organizations evolve from top-down, authoritarian structures to cultures of trust, inclusion, and generosity. His experience spans advising CEOs of major corporations to hands-on coaching with emerging leaders. He is the author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain,” a groundbreaking book that reimagines the connection between caring leadership and delivering results. Joe is currently an advisor and coach to BCG's rising partners, teaching them how to inspire, motivate, and build lasting client relationships. You can reach Joe and learn more about his work via his LinkedIn profile or his website at joedavis.com. Show References and Resources “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain” by Joe Davis Amazon Link Joe Davis on LinkedIn: https://www.linkedin.com/in/joe-davis-bcg/ Joe's personal website: https://joedavis.com Harvard Business School: https://www.hbs.edu Boston Consulting Group (BCG): https://www.bcg.com Michigan State University's Trust and Leadership Education: https://broad.msu.edu CEO Joaquin Duato, Johnson & Johnson: https://www.jnj.com/leadership/joaquin-duato Scott Kirby, CEO of United Airlines: https://www.united.com/ual/en/us/fly/company/about/leadership.html Sheila Bair, former FDIC chair: https://www.fdic.gov/about/leadership/sheila-bair/ Thank you for listening to the Delighted Customers podcast!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Wells Fargo Senior Economist Sarah House leads "The Jackson 5" analysis of key economic indicators ahead of the Fed symposium. Wedbush's Matt Bryson explains his Nvidia price target hike this week ahead of earnings. Brooke May from Evans May Wealth charts the market's next move. Plus, an exclusive look inside one of America's largest biologic drug manufacturing plants as Fujifilm's North Carolina facility prepares to produce drugs for Johnson & Johnson and Regeneron. Tom Rogers, former NBC Cable President and Versant Board senior advisor, breaks down the streaming wars as ESPN launches its new standalone app. 

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Gina Torres, a nurse-turned-medical device sales professional at Johnson & Johnson, to unpack what it really takes to thrive in one of the most competitive fields in healthcare: peripheral vascular and coronary sales. Gina shares her inspiring journey from working multiple nursing jobs to consolidating her career into one life-changing role in medical device sales. She reveals how she broke into the industry, why she chose Shockwave's groundbreaking intravascular lithotripsy technology, and what makes the clinical specialist role such a powerful entry point for both clinicians and driven non-clinicians. From balancing 5 a.m. case starts to late-night procedures, Gina gives a behind-the-scenes look at the unpredictable but rewarding life of a vascular rep. She also breaks down the income potential, the skills that truly separate top performers, and why grit, empathy, and the ability to “get comfortable being uncomfortable” matter more than a clinical background. Whether you're a nurse considering the leap, a bachelor's graduate wondering if you can compete, or an aspiring sales rep curious about cardiovascular devices, this conversation delivers raw insights, career strategies, and real talk about success in medical sales. Connect with Gina: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

In this episode, hosts Mark Longo and Dan Passarelli (Market Taker Mentoring) delve into various listener-submitted questions and trading strategies. They talk about a listener's in-depth query on a put calendar trade with Johnson & Johnson and its associated risks, and another listener's covered call strategy dubbed 'Ultra Premium Harvesting.' The hosts also answer inquiries on the use case and risks involved in trading inverse volatility products like SVXY, and discuss the optimal products and strategies for trading precious metals like gold and silver. Additionally, they address a listener's request about visiting the studio and potential local meet-ups.   01:12 Welcome to Options Bootcamp 03:10 Listener Mail Call 03:57 Ben's Epic Treatise on Put Calendars 11:39 Michael K's Ultra Premium Harvesting Strategy 17:00 Exploring Inverse Volatility Products 20:21 Trading Precious Metals 23:21 Listener Annet's Chicago Visit 25:08 Conclusion and Upcoming Episodes  

In this episode of the People of Packaging podcast, host Adam Peek sits down with Michael Houston, President & CEO of Future Blue Group and Co-founder of Shower Pouch, for an insightful conversation that delves into his extensive career in packaging and his passion for innovative, sustainable solutions.Michael's Journey: From Corporate Giants to Entrepreneurial VenturesMichael shares his impressive career trajectory, starting with his time at major CPG companies like Procter & Gamble and Johnson & Johnson, where he gained invaluable experience in packaging R&D and operations. He later transitioned to companies like Beachbody, where he began to focus on helping smaller businesses navigate the complexities of product development and market entry. His experience also includes roles at Unilever, working with beauty brands like Murad, Dermalogica, and Kate Somerville, and contributing to the Honest Company's IPO. This rich background has fueled his current entrepreneurial pursuits.Introducing Shower Pouch: The On-the-Go Hygiene SolutionA significant portion of the discussion revolves around Shower Pouch, a product born from a personal problem statement. Michael recounts how his father, serving in Afghanistan, highlighted the need for a better hygiene solution than just baby wipes. Collaborating with his business partner, Omar Jimenez (a talented chemist), they developed Shower Pouch – a high-quality, durable, and highly absorbent non-woven wipe designed to clean an entire body with just one product. The conversation touches on:* The Problem: Addressing the need for convenient and effective hygiene solutions for military personnel, hospital patients, and even active individuals on the go.* The Innovation: The use of a specialized non-woven material that is highly absorbent and durable, allowing for efficient cleaning.* Sustainability Focus: Shower Pouch is designed as a durable good, emphasizing reusability and minimizing waste. The packaging even suggests washing and repurposing the wipes.* Convenience: The product can be used on its own or heated for a more comfortable experience.* Availability: Shower Pouch is available on Amazon Prime and through their website, theshowerpouch.com.Future Blue Group: Driving Sustainable Packaging for CPG BrandsMichael's consultancy, Future Blue Group, leverages his deep industry knowledge to assist CPG brands in various aspects of packaging. The discussion highlights:* Key Areas of Focus: Future Blue Group helps brands with cutting-edge technical packaging solutions, cost reduction, enhancing packaging aesthetics, improving customer experience, integrating sustainability principles, optimizing supply chain operations, and accelerating market entry.* Industry Successes: Michael notes significant success working with brands in the supplement space, where he helps optimize packaging for shelf stability and manufacturability, moving beyond generic stock options. He also finds considerable success in the personal care, masstige, and prestige categories, where he navigates complex material and formulation challenges to ensure both aesthetics and functionality.* The Importance of Data: Michael emphasizes the critical role of data in making informed packaging decisions. He advocates for a scientific, objective approach to sustainability, starting with verifiable data rather than relying on "greenwashing" or gut feelings. This is where tools like Specright.com and Trayak become invaluable.Sustainability in Packaging: A Call for ClarityMichael offers crucial advice for brands tackling sustainability:* Define Your Sustainability: He stresses the importance of clearly defining what sustainability means for your specific brand – whether it's compostability, recyclability, durability, or a combination. A clear definition allows for quantifiable goals and avoids being "all over the place."* Embrace Material Science: Understanding the materials you're working with, their manufacturing processes, and their environmental impact is key to making truly sustainable choices.* Beyond Greenwashing: Move past superficial claims and commit to science-based decisions that genuinely reduce environmental impact, particularly focusing on reducing CO2 emissions.Connect with Michael Houston:* LinkedIn: Michael Houston* Future Blue Group: Find them on LinkedIn* Shower Pouch: theshowerpouch.com* Email: michael.houston@futurebluegroup.com This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.packagingisawesome.com

Carl Quintanilla and Jim Cramer explored what to make of a second day of bank earnings, led by Bank of America, Goldman Sachs and Morgan Stanley. The chip sector's record run also in the spotlight, led by Nvidia trading at all-time highs. The anchors reacted to comments made by Nvidia CEO Jensen Huang in Beijing about doing business in China. The Producer Price Index for June comes in tamer than expected, showing wholesale inflation unchanged month-on-month. Also in focus: ASML drags chip equipment stocks lower, Johnson & Johnson jumps on earnings, President Trump from trade to your 401(K), crypto legislation vote watch. Squawk on the Street Disclaimer

The title is a joke, but it's funny...and who knows, maybe it'll happen. Biggest brand deal ever? lol.Membership Specials https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com